Sparsomycin (Sc-Rs) derivative; pharmaceutical composition having anti-tumor activity

摘要

The invention concerns novel sparsomycin (Sc-Rs) derivatives having superior cytostatic activity compared to sparsomycin itself. Said derivatives contain a lipophilic group R2, selected from C2-C20-alkyl, aryl, aralkyl and alkaryl, which is preferably n-octyl or benzyl.